Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Core Laboratories (CLB) EBIT (2022 - 2025)

Core Laboratories' EBIT history spans 4 years, with the latest figure at -$31.0 million for Q4 2025.

  • For Q4 2025, EBIT fell 318.7% year-over-year to -$31.0 million; the TTM value through Dec 2025 reached $9.6 million, down 83.54%, while the annual FY2025 figure was $9.6 million, 83.54% down from the prior year.
  • EBIT reached -$31.0 million in Q4 2025 per CLB's latest filing, down from $20.9 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $20.9 million in Q3 2025 to a low of -$31.0 million in Q4 2025.
  • Average EBIT over 4 years is $11.0 million, with a median of $14.6 million recorded in 2022.
  • Peak YoY movement for EBIT: soared 62.26% in 2023, then plummeted 318.7% in 2025.
  • A 4-year view of EBIT shows it stood at $15.6 million in 2022, then fell by 6.64% to $14.6 million in 2023, then decreased by 2.79% to $14.2 million in 2024, then tumbled by 318.7% to -$31.0 million in 2025.
  • Per Business Quant, the three most recent readings for CLB's EBIT are -$31.0 million (Q4 2025), $20.9 million (Q3 2025), and $15.3 million (Q2 2025).